Drug class | Drug | Terminal halve life | Authorised with dose-loading in AIRDs / other disease? | Loading schedule | Cost per patient year with loading dosea | Cost per patient year without loading dosea | Euro/ % increase medication costs due to dose-loading for full year use |
---|---|---|---|---|---|---|---|
TNFi | Adalimumab | 14 days | No / Yes | NA | |||
Certolizumab | 14 days | Yes / NA | 400 mg weeks 0,2,4, instead of 200 mg | €14,459 | €12,965 | €1495 / 11.5% | |
Etanercept | 3 days | No / Yes | NA | ||||
Golimumab | 12 days | No / Yes | NA | ||||
Infliximab (RA) | 9 days | Yes / Yes | 3 mg/kg weeks 0,2,6 and 14, instead of 8 weeklyb | €12,940 | €11,323 | €1617 / 12.4% | |
Infliximab (PsA/axSpA) | 9 days | Yes / Yes | 5 mg/kg weeks 0,2,6 and 14, instead of 8 weeklyb | €17,254 | €15,097 | €2157 / 12.5% | |
Anti-CD20 | Rituximab | 6–62 days | No / No | NA | |||
Anti CD80/86 | Abatacept i.v. | 14 days | Yes / No | 750 mg weeks 0,2,4 instead of weeks 0,4c | €15,996 | €14,853 | €1143 / 7.1% |
Abatacept s.c. | 14 days | Yes / NA | Start with 750 mg i.v. instead of once weekly scc | €15,199 | €14,056 | €1143 / 7.5% | |
IL-1 receptor antagonist | Anakinra | 5 h | No / No | NA | |||
Anti-IL6 receptor | Sarilumab | 9 days (initial) | No / No | NA | |||
Tocilizumab i.v. | 3 days | No / No | NA | ||||
Tocilizumab s.c. | 13 days | No / No | NA | ||||
Anti-IL-17A | Secukinumab 150 mg | 27 days | Yes / Yes | Weeks 0,1,2,3,4, instead of monthly | €9357 | €7486 | €1871 / 20% |
Secukinumab 300 mg | 27 days | Yes / Yes | Weeks 0,1,2,3,4, instead of monthly | €18,714 | €14,972 | €3742 / 20% | |
Ixekizumab | 13 days | Yes / Yes | 160 mg instead of 80 mg week 0 | €16,116 | €14,965 | €1151 / 7.1% | |
Anti-IL-12/23 | Ustekinumab | 21 days | Yes / Yes | Additional injection at week 4c | €16,023 | €12,819 | €3204 / 20% |